Table 1.
Selected ongoing trials in antibody-based therapies across different cancer types (clinicaltrials.gov, accessed on 1 March 2024).
| Condition | Intervention | Format | Gov. Identifier | Phase | Status | Enrollment |
|---|---|---|---|---|---|---|
| Immune checkpoint inhibitors | ||||||
| Metastatic hepatocellular carcinoma (HCC) | Cobolimab (anti Tim3), Dostarlimab (anti PD-1) | Humanized IgG4 | NCT03680508 | II | Recruiting | 42 |
| Advanced solid tumor | BND-22 (anti-LILRB1) monotherapy or in combination with Pembrolizumab (anti-PD-1) or Cetuximab (anti EGFR) | Humanized IgG4 | NCT04717375 | I/II | Recruiting | 456 |
| Stage IV NSCLC | Nivolumab Ipilimumab plus chemotherapy (Carboplatin Paclitaxel Pemetrexed Cisplatin) |
-- | NCT03215706 | III | Active, not recruiting | 719 |
| Metastatic squamous HNSCC | Durvalumab in combination with small-molecule antagonists of CXCR2 and STAT3 |
IgG1 | NCT02499328 | I/II | Active, not recruiting | 340 |
| Hormone-sensitive prostate cancer | Nivolumab monotherapy or in combination with BMS-986253 (anti-IL8) | -- | NCT03689699 | I/II | Active, not recruiting | 60 |
| Advanced solid tumor | Uliledlimab (anti- CD73) Toripalimab (anti-PD-1) |
Humanized mAb | NCT04322006 | I/II | Recruiting | 376 |
| Antibody –drug conjugates | ||||||
| HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer | T-DM1 (Trastuzumab Emtansine) Atelizumab (anti PD-L 1) |
- | NCT04740918 | III | Active, not recruiting | 96 |
| Pre-treated HER2 breast cancer | T-Dxd (Trastuzumab Deruxtecan) Capecitabine Lapatinib Trastuzumab |
- | NCT03523585 | III | Active, not recruiting | 608 |
| Advanced solid tumor | SGN-B7H4V (B7-H4 targeted ADC) | - | NCT05194072 | I | Recruiting | 430 |
| Relapsed or refractory DLBCL | Loncastuximab Tesirine in combination with Rituximab | NCT04384484 | III | Recruiting | 350 | |
| Bispecific Antibodies (bsAb) | ||||||
| Advanced solid tumors | IOS-1002 (anti- LILRB1, LILRB2, KIR3DL1) monotherapy or in combination with Pembrolizumab | HLA-B57-Fc fusion protein | NCT05763004 | Ia/Ib | Recruiting | 140 |
| CDX585 (anti-LILRB2, PD-1) | IgG1k | NCT05788484 | I | Recruiting | 130 | |
| Advanced hepatobiliary cancer | Volrustomig (anti-PD-1, CTLA-4) Or Rilvegostomig (anti-PD-1, TIGIT) as monotherapy or in combination With Carboplatin Gemcitabine Cisplatin |
IgG1 Humanized IgG1 |
NCT05775159 | II | Recruiting | 260 |
| High risk locally advanced cervical cancer | Volrustomig (anti- PD-1, CTLA-4) | IgG1 | NCT06079671 | III | Recruiting | 1000 |
| EGFR-mutant locally advanced or metastatic non-squamous NSCLC | Ivonescimab (anti PD-1/VEGF) | Humanized IgG1 | NCT05184712 | III | Recruiting | 470 |
| Refractory small cell lung cancer (SCLC) | Tarlatamab (engages DLL3, CD3) | bsTCE | NCT05060016 | II | Active, not recruiting | 222 |
| Metastatic castration-resistant prostate cancer (mCRPC) | Gammabody® (engages Vγ2Vδ9, PSMA) | Bs γδTCE | NCT05369000 | I/II | Recruiting | 66 |
| Other monoclonal antibodies (mAbs) | ||||||
| Metastatic HCC | Humax-IL8 (anti IL-8) or Cabiralizumab (anti-CSF1-R) in combination with Nivolumab |
Humanized IgG1K -- |
NCT04050462 | II | Active, not recruiting | 23 |
| Treatment naïve advanced melanoma or RCC | Sotigalimab (CD40 agonist mAb)\ Nivolumab Ipilimumab |
-- | NCT04495257 | I | Recruiting | 36 |